Secondary Logo

Journal Logo

Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream: Erratum

doi: 10.1097/CMR.0b013e32835c7e15
ERRATUM
Free

The authors of the article ‘Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream’ that was published in the June issue this year would like to make readers aware that the following sentence that were published in the article should be corrected as shown below:

In the abstract the sentence ‘Additional studies are needed to determine whether this therapy is associated with a survival benefit.’ should read ‘Future studies are needed to determine whether this therapy is associated with survival benefit’.

In the first sentence of the discussion ‘Although this study is limited to just three patients...’ (p240) should be changed to ‘Although this report is limited to just three patients ...’.

In the discussion paragraph beginning with ‘With respect to this study, it is important to note that a tumor-specific systemic immune ...’ (p242), the sentence should have read ‘With respect to this report, it is important to note that a tumor-specific systemic immune ...’.

In the last paragraph of the Discussion the sentence ‘We are aware of several other limitations to this study’. (p243) should have read ‘We are aware of several other limitations to this report 1’.

The authors apologise for these errors.

Back to Top | Article Outline

Reference

1. Garcia MS, Ono Y, Martinez SR, Chen SL, Goodarzi H, Phan T, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res. 2011;21:235–243
© 2013 Lippincott Williams & Wilkins, Inc.